Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE The results of the meta-analyses indicate that rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737 are significantly associated with a higher risk for PCa for at least one race, whereas the variants rs13254738 and rs7000448 are not. 22382457

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE In conclusion, this is the first study showing that prostate cancer risk variants, such as rs16901979, might improve outcome prediction following ADT, thus allowing identification of high-risk patients who might benefit from appropriate adjuvant therapy. 21445969

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE A meta-analysis across 10 studies including our results of four 8q24 variants (rs1442295 and DG8S737-region 1, rs16901979-region 2, and rs6983267-region 3) and prostate cancer risk demonstrated strong associations across a wide array of study designs and populations. 18231127

2008

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE We demonstrate that trans-acting RNA molecules facilitating resistance to androgen depletion (RAD) in vitro and castration-resistant phenotype (CRP) in vivo of PC contain intergenic 8q24-locus SNP variants (rs1447295; rs16901979; rs6983267) that were recently linked with increased risk of PC. 22067658

2011

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Significant differences (P < 0.00185) between the two subtypes were observed for rs16901979 (8q24) and rs1859962 (17q24), which were enriched in TMPRSS2:ERG fusion-negative (OR = 0.53, P = 0.0007) and TMPRSS2:ERG fusion-positive PrCa (OR = 1.30, P = 0.0016), respectively. 27798103

2016

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE The rs16901979 CA genotype carriers had a higher risk of prostate cancer than the CC genotype. 22583965

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE SNPs rs6983561, rs7008482, and rs16901979 were significantly associated with CaP risk in WAs (P < 0.03). 22234922

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Two of these 17 SNPs, located at 3p12, and region 2 at 8q24, were significantly associated with prostate cancer risk (P < 0.05), and only SNP rs16901979 at region 2 of 8q24 remained significant after accounting for 20 tests. 19549807

2009

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Forty-nine tagging SNPs including three previously reported significant variants (rs1447295, rs6983267, rs16901979) and seven variants in the 5' upstream region of the MYC proto-oncogene were tested for association with susceptibility to PC and tumor aggressiveness in 596 histologically verified PC cases and 567 ethnically matched controls. 19562729

2009

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE In summary, the A allele at rs16901979 was associated with the risk of prostate cancer in the Caribbean population of Guadeloupe, confirming its involvement in populations of African descent. 25130587

2016

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Three 8q24 polymorphisms (rs1447295 C>A, rs16901979 C>A, and rs6983267 T>G) have been extensively investigated for their association with prostate cancer (PCa) susceptibility, yet conclusions are contradictory. 26159557

2015

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Therefore, this meta-analysis demonstrated that 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) were associated with the susceptibility to PCa, which held the potential biomarkers for PCa risk. 29158792

2017

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE There was no joint effect between SNPs rs16901979 A and rs6983267 G. These results confirm the significance of these SNPs in prostate cancer etiology in a previously unstudied population who do not undergo prostate cancer screening and are diagnosed with severe disease. 18768513

2008

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE In particular, both homozygous AA and heterozygous CA genotypes of rs16901979, as well as the AA and CA genotypes of rs1447295, were associated with the risk of prostate cancer. 30061842

2018

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE We report that rs7008482, which maps to the 8q24.13 region, is an additional independent prostate cancer risk variant (P = 5 x 10(-4)), and we also replicate the association of rs16901979 with prostate cancer (P = 0.002). 17978284

2007

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE SNP rs16901979 in region 2 was associated with significantly increased risk of prostate cancer (OR = 1.41, 95% confidence interval [CI] 1.02-1.95, P = 0.04) with the risk stronger in men with early-onset prostate cancer (OR = 2.37, 95% CI 1.40-3.99, P = 0.001). 21557270

2011

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE The variants rs16901979 and rs6983561 at 8q24 are associated with prostate cancer risk in Taiwanese men. 19908238

2010

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE We demonstrate that trans-acting RNA molecules facilitating resistance to androgen depletion (RAD) in vitro and castration-resistant phenotype (CRP) in vivo of PC contain intergenic 8q24-locus SNP variants (rs1447295; rs16901979; rs6983267) that were recently linked with increased risk of PC. 22067658

2011

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE Analysis of the National Cancer Institute's Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer association study database alone and in combination with our data provided further evidence for this second prostate cancer risk locus; in the combined analysis, the allele frequencies for rs6983267 differed statistically significantly between case patients and control subjects (P = 1.61 x 10(-9)). 17925536

2007

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE Three 8q24 polymorphisms (rs1447295 C>A, rs16901979 C>A, and rs6983267 T>G) have been extensively investigated for their association with prostate cancer (PCa) susceptibility, yet conclusions are contradictory. 26159557

2015

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE Therefore, this meta-analysis demonstrated that 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) were associated with the susceptibility to PCa, which held the potential biomarkers for PCa risk. 29158792

2017

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE These included correlations between an intergenic CpG site at Chr8:128393157 and the prostate cancer SNP rs16902094 (ρ = -0.54; P = 9.7 × 10(-7); q = 0.002), a PRNCR1 CpG site at Chr8:128167809 and the prostate cancer SNP rs1456315 (ρ = 0.52; P = 1.4 × 10(-6); q = 0.002), and two POU5F1B CpG sites and several prostate/colorectal cancer SNPs (for Chr8:128498051 and rs6983267, ρ = 0.46; P = 2.0 × 10(-5); q = 0.01). 25315430

2014

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE A single nucleotide polymorphism (SNP) rs6983267, located within the 8q24 region, is strongly associated with risk of colorectal and prostate cancer. 19895682

2009

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE A combined analysis with four additional studies (total: 4,296 cases and 4,299 controls) confirms association with prostate cancer for rs6983267 in the centromeric locus (P = 9.42 x 10(-13); heterozygote odds ratio (OR): 1.26, 95% confidence interval (c.i.): 1.13-1.41; homozygote OR: 1.58, 95% c.i.: 1.40-1.78). 17401363

2007

dbSNP: rs6983267
rs6983267
0.800 GeneticVariation BEFREE Single nucleotide polymorphisms (SNPs) rs6983561 and rs6983267 showed the strongest evidence of prostate cancer association. 18360876

2008